for starting clinic. programs our first with novel to in progress therapeutic vivo candidate about good as initial of talk to the you, Indeed to transthyretin John, Thank time would and our and amyloidosis our development or like this is ATTR. treatment we I continue the pipeline an us morning. exciting for NTLA-XXXX, modality our validate
you As leading in multiple the of protein neuropathy and liver results that cardiomyopathy. [indiscernible] a manifestations, disease deposition the and production disease to is diverse peripheral progressive TTR in fatal protein the organs, fibroids from including and of know, ATTR insoluble TTR
hereditary with the patients the are XXX because estimated manifest to hereditary form genetic of treat to gene. regardless patients be have Over approximately the our a either causing patients affects across mutation, underlying With can whether out which XXX,XXX ATTR, XX,XXX knocking Furthermore, ATTR of goal known to will disease, wild-type is TTR which we the genetic absence known spontaneously develop ATTR globe. affects also mutations at worldwide. they or of in ATTR the disease an NTLA-XXXX as XXX,XXX wild-type
to the potential the fundamental few a both mission, treatment true curative validated differentiating hope patients an approach. potentially way a made the premise key TTR with peers need our reducing that patients have of with ATTR. believe we achieve our protein strides years, have target clinical those that for as and They is provide certain results to effective tremendous We and editing of a CRISPR/CasX our Over to address on factor to of represents past one-time shown gene and to expression benefit. build and in
demonstrated Today, LNT TTR nonhuman gene potential our studies in we targeting primates. have this lead in formulation with the
of an nonhuman achieved be to greater Following in which a of single expected TTR reduction primates XX% administration, circulating average is efficacious. clinically we than
liver study, TTR durability demonstrated months we with editing the of XX ongoing proteins. durable of of reduction part sustained As circulating have
advance are We continue enabling to pleased IND and with studies. very our results these
XXXX, NTLA-XXXX first our that commenced we also expect have in in the we delivered CRISPR/CasX an systemically we Phase submit on We remain materials today for clinical therapy X mid be clinic. application track to importantly and the manufacturing which scale announced to IND for
Regeneron for XX-XX with co-commercialization a co-development a As program, Intellia have and reminder, with agreement this the as party. lead we
to efforts the our Let's now turn target insertion in liver. and
we've of into insertion this transgene Factor primates liver first the demonstrated locus. As discussed the prior using mediated IX CRISPR/CasX on calls, in nonhuman targeted inserted albumin
that proprietary delivery used which vehicle protein the clotting CRISPR is our reminder, AAV vector system combines a with Factor an IX missing gene. defective patients. LNP the study Factor B As hemophilia blood or hybrid our [ph] encoding delivery in IX This echos
delivery modularity as the the the the believe platform, traditional both system in advantages our vectors. CRISPR ATTR gene provides therapy same LNP In demonstration our key Targeted retroviral We our program insertion and over of guide of being change should the to a due RNA. of sole in targeted one risk used is the mutagenesis with efficacy. safety integration approach the of nice insertion reduce random
durable a provide should insertion disease. treatment potentially targeted of addition, cure with single course and efficacy the In
program the other simultaneously in So working are support to expansion B we and hemophilia exploring of to our pipeline. been identify next the steps insertion for of vivo have with transgenes Regeneron the
interest the this we highlighting of hybrid system. have part and AAV delivery only template the of LNP in As the modularity effort, the again our or exchanged gene of approach, DNA
and insertion additional our expression with interest genes at protein this of look IX more. for are to vivo meetings. evaluating upcoming on Building we These and factor alpha-X scientific forward work in and science results highly two innovative we several generated antitrypsin, now are presenting have encouraging
restoration dose model demonstration June the vivo Annual [ph] and reported knockout ESGCT or The level AATD. disease reduction in At requires of relevant to and wild-type of levels of a restoration a than first we've led and disease-causing This the in therapeutically disease. deficiency study. period protein throughout disease-causing the circulating protein insertion gene on alpha-X protein and the reduction the ameliorate the sustained of antitrypsin XX% through the protein of mouse the XXXX Meeting edits consecutive to of in consecutive missing protein greater this the a
another addresses as differentiated presents compelling editing treating approach and believe the it of example in of manifestations to lung AATD this leadership therapeutic We is sustaining both genetic Moreover, for diseases. our liver and this the genome disease.
species. higher moving We AATD with be strategy forward for consecutive will editing our in animal
cell a Moving engineered range are we cells hematological pipeline, therapy our of solid treat engineered tumors. designing to on and to
our streams focus end, on we As have cell today be receptor work replacement TCR this our T approach. four we've discussed on will calls, or towards prior wholly-owned so
utilizing we and myeloid Initially to tumors. and are Wilms a Tumor variety then leukemia potentially target additional approach of for X liquid solid this acute
endogenous As healthy can alpha-beta in we by donors. efficient our in-locus. naturally therapeutic occurring out a chain proprietary found highly the a simultaneously the insert eliminating and that the TCRs TCR TCR therapeutic the Relatively approach is TCR inserts based be precisely and TCR reminder, knocks
enable or normal and CAR-Ts the TCRs, should these versus endogenous and recognize typically host TCRs. that inserted CAR-Ts disease antigens physiology, result on of stabilize expand set therapeutic they because expression sparring reduce the range between In cell to approach TCRs inserted of enhance types T could of the recognized contrast addressable graft tumor of This from a proteins. us risk surface preserve and broad the to can tumor
and currently lead will approach safety In therapy available cell over therapy engineered treatment. TCR efficacy advantages [ph] addition, offers directed our engineered we cell meaningful
outcomes medical the overall patients is AML or with leukemia myeloid of for the blood acute AML majority XX%. bone five-year unmet rate of know, By a of than Generally develop marrow and significant patient's treatment poor and and of towards you the antigen As less cancer broadly is AML Tumor applicable believe opportunity is the the need. to patients, survival Wilms’ directing of mutation TCRs majority which AML the in provides overexpressed it X leukemia. tremendous for regardless we background remained
the from AML we affinity. [ph] our candidates on patient are studies recognize epitope xenograft which nomination these our of the in candidate achieve lead primary year will functional models that derived to quarter's interest testing WTI [ph] of by on discussed call, inform we currently TCR end. last As ongoing track conducting high WTX in multiple Data of development remain with
a program In foundation tumors. will cancers related are and a in broad to solid of support array of pursue our including clinical X lay parallel believe manufacturing GMP we We development trial. advancing the AML ongoing to studies, activities Phase
As to tumor with there across activity significant in lines. and promising highly begun same tumor types liquid TCR. the in is And opportunity solid number vitro WTX solid a tumor we've expressed types, many target to of subsequent generate cell is
expand pipeline. We immuno-oncology new opportunities expect unlock will this to further our work
Glenn that, to third turn to the go quarter's would the like call over financial statement. who With I will through
